tobemstomig + platinum-based chemotherapy

**Tobemstomig + platinum-based chemotherapy** is an investigational combination regimen for cancer therapy, primarily evaluated in non-small cell lung cancer (NSCLC)[1][2][3][5][7]. Tobemstomig (RO7247669, RG-6139) is a bifunctional bispecific monoclonal antibody that simultaneously binds to the immune checkpoint receptors programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) on T cells, antagonizing both to enhance cytotoxic T cell activity and reinvigorate antitumor immune response[2][4][8]. Platinum-based chemotherapy refers to standard antineoplastic regimens (such as carboplatin or cisplatin, frequently combined with pemetrexed or paclitaxel), which cause DNA crosslinking and apoptosis in tumor cells. Together, this combination aims to combine immune-checkpoint blockade with established cytotoxic chemotherapy. Clinical trials are currently comparing this regimen to the standard-of-care pembrolizumab plus platinum-based chemotherapy in previously untreated advanced or metastatic NSCLC[1][3][5][7].

Other names

Anti PD-1 anti LAG-3 bispecific antibody + platinum-based chemotherapyanti-PD-1/anti-LAG-3 bispecific antibody + platinum-based chemotherapyPD1-LAG3 BsAb + platinum-based chemotherapy